Rankings / Cardiovascular & Lipids
Obicetrapib
CV/Lipid · CETP inhibitor (next-generation)
Tier B+
What this is
Revival of CETP inhibition after the torcetrapib (BP/mortality) and dalcetrapib (futile) failures. Obicetrapib's hydrophilic structure avoids torcetrapib's off-target effects. BROADWAY trial: -32% LDL on top of max statin. Triple combo (obicetrapib + ezetimibe + statin) ranks highest in 2026 network meta for LDL/ApoB reduction. Will compete with bempedoic acid and PCSK9i for the statin-add-on niche.
Mechanism
Highly selective hydrophilic CETP (cholesteryl ester transfer protein) inhibitor; blocks transfer of cholesteryl esters from HDL to ApoB-containing particles, lowering LDL/ApoB while raising HDL; differs from torcetrapib/anacetrapib in cleaner off-target profile
Dose & route
10 mg PO once daily
Citations
- https://doi.org/10.1161/JAHA.125.047676
- https://doi.org/10.1097/FJC.0000000000001785
- https://doi.org/10.14740/jocmr6523
Links go to the source. If a link is dead or you want something re-checked, let me know.
This is an independent synthesis of published research by a non-clinician. Scores are opinions supported by citations, not prescriptions. See the full disclaimer and methodology for how this score was produced and what it does and doesn't mean.